Related Experiment Video

Updated: Aug 14, 2026

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant
08:52

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant

Published on: May 27, 2011

GVAX (Cell Genesys)

R Dummer1

  • 1Department of Dermatology, University Hospital of Zürich, Switzerland. dummer@derm.unizh.ch

Current Opinion in Investigational Drugs (London, England : 2000)
|September 27, 2001
PubMed

Insights

GVAX, a cancer vaccine developed by Cell Genesys, is undergoing clinical trials for multiple tumor types. A high-potency version is now in trials following positive early results for this promising cancer immunotherapy.

Area of Science:

  • Oncology
  • Immunotherapy
  • Vaccine Development

Background:

  • Cell Genesys is developing GVAX, a cancer vaccine.
  • GVAX targets various tumor types including melanoma, renal, lung, pancreatic, prostate cancers, and multiple myeloma.
  • The company was formerly known as Somatix Therapy Corp.

Purpose of the Study:

  • To evaluate the efficacy and safety of GVAX cancer vaccine across multiple cancer types.
  • To assess a high-potency version of GVAX for prostate cancer.
  • To explore GVAX applications through clinical trials and collaborations.

Main Methods:

  • Clinical trials for GVAX have been initiated for several cancer types.
  • Phase I and II trials are planned for leukemia and pancreatic cancer.
  • A collaboration with Japan Tobacco is in place for prostate cancer trials, with potential expansion.

Main Results:

  • Encouraging Phase II data has been reported for the first-generation GVAX prostate cancer vaccine.
  • A high-potency version of GVAX, releasing increased immune stimulants, has entered trials.
  • Japanese clinical trials were temporarily halted due to cell production issues.

Conclusions:

  • GVAX shows potential as a cancer vaccine for various malignancies.
  • Further clinical development, including a high-potency formulation, is ongoing.
  • The development of GVAX highlights advancements in cancer immunotherapy.

More Related Videos

Expansion and Enrichment of Gamma-Delta (γδ) T Cells from Apheresed Human Product11:51

Expansion and Enrichment of Gamma-Delta (γδ) T Cells from Apheresed Human Product

Published on: September 22, 2021

A GMP-Compliant Procedure for the Generation of Gene-Modified T cells06:47

A GMP-Compliant Procedure for the Generation of Gene-Modified T cells

Published on: October 6, 2023

Related Concept Videos

Zygotic Development And Stem Cell Formation01:10

Zygotic Development And Stem Cell Formation

The development of all multicellular organisms starts with the fusion of haploid cells called sperm and egg to form a diploid zygote. A zygote is a totipotent cell that can develop into a complete organism. The zygote undergoes cell division or cleavage to form an 8-cell mass. Until this stage, the cells are spherical, loosely attached, and remain totipotent. Totipotent cells are capable of developing both the embryonic and the extraembryonic tissues. However, as they continue to divide, they...
iPS Cell Differentiation01:22

iPS Cell Differentiation

The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
Cells of the Adaptive Immune Response01:23

Cells of the Adaptive Immune Response

The T and B lymphocytes of the adaptive immune system develop from common lymphoid progenitor cells in the bone marrow. These progenitors give rise to precursors that eventually develop into both T and B lymphocytes. As these precursors mature, they gain the ability to detect and respond to foreign antigens in the body, a process known as immunocompetence. Additionally, these precursors acquire self-tolerance, a process that ensures they do not react to self-antigens. This intricate system...
B Cell Activation and Differentiation01:24

B Cell Activation and Differentiation

The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Vaccine Production01:23

Vaccine Production

Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...